-
Posted by
Two Blokes Tue at 12:45 PM -
Filed in
Stock
-
2 views
Repeated positive recommendation from Data Safety Monitoring Board (“DSMB”) of pivotal Phase 3 study for lead clinical candidate Bria-IMT\u2122 in combination with checkpoint inhibitor Bria-IMT has received Fast Track designation from FDA and patient enrollment has been accelerating in the pivotal Phase 3 study in metastatic breast cancer Successful completion of the pivotal study may lead to a Biologics License Application submission, Priority Review, Full Approval, and commercialization Interim analysis planned after 144 events (deaths) in Phase 3 Study Phase 2 survival data superior to reported standard of care including TRODELVY\u00ae (sacituzumab govitecan-hziy) in similar hormone receptor positive (HR+) metastatic breast cancer patients Promising early results for OTS platform technology with resolution of breast cancer metastasis in first patient dosed PHILADELPHIA and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to issue a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO.
